La vendita allo scoperto per Verrica Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Verrica Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Verrica Pharmaceuticals (NASDAQ:VRCA) Azioni, Report sulle vendite allo scoperto

Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals Inc

UBS analyst Taylor McGinnis maintains Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) with a Buy and lowers the price target from $22 to $19.

News

Price Target

Analyst Ratings

FRSH

UBS Maintains Buy on Freshworks, Lowers Price Target to $19

UBS analyst Ashwani Verma maintains Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Neutral and lowers the price target from $47 to $41.

CYTK

UBS Maintains Neutral on Cytokinetics, Lowers Price Target to $41

UBS analyst Taylor McGinnis maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and lowers the price target from $55 to $35.

FIVN

UBS Maintains Buy on Five9, Lowers Price Target to $35

UBS analyst Damian Karas maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Buy and lowers the price target from $56 to $53.

CGNX

UBS Maintains Buy on Cognex, Lowers Price Target to $53

UBS analyst Peter Grom maintains Church &amp; Dwight Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>) with a Neutral and lowers the price target from $110 to $102.

UBS Maintains Neutral on Church & Dwight Co, Lowers Price Target to $102

UBS analyst John Lovallo maintains Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) with a Buy and lowers the price target from $180 to $163.

BLDR

UBS Maintains Buy on Builders FirstSource, Lowers Price Target to $163

UBS analyst Joshua Spector maintains Air Products &amp; Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) with a Buy and lowers the price target from $335 to $324.

UBS Maintains Buy on Air Products & Chemicals, Lowers Price Target to $324

UBS analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Buy and lowers the price target from $355 to $310.

UBS Maintains Buy on Bio-Rad Laboratories, Lowers Price Target to $310

UBS analyst Trung Huynh maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Neutral and lowers the price target from $319 to $315.

AMGN

UBS Maintains Neutral on Amgen, Lowers Price Target to $315

Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) has outperformed the market over the past 5 years by 8.33% on an annualized basis producing an average annual return of 22.97%. Currently, Devon Energy has a market capitalization of $20.23 billion. 
Buying $100 In DVN: If an investor had bought $100 of DVN stock 5 years ago, it would be worth $275.31 today based on a price of $31.44 for DVN at the time of writing.
<h3>Devon Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746225912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Devon Energy 5 Years Ago Would Be Worth This Much Today

UBS analyst Esther Rajavelu maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $331 to $349.

ALNY

UBS Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $349

UBS analyst Kevin Caliendo maintains Alignment Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) with a Neutral and raises the price target from $16 to $17.

ALHC

UBS Maintains Neutral on Alignment Healthcare, Raises Price Target to $17

UBS analyst Joseph Spak maintains Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) with a Neutral and raises the price target from $58 to $66.

APTV

UBS Maintains Neutral on Aptiv, Raises Price Target to $66

UBS analyst Gavin Parsons maintains Howmet Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) with a Neutral and raises the price target from $120 to $155.

UBS Maintains Neutral on Howmet Aerospace, Raises Price Target to $155

UBS analyst Karl Chalabala maintains Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Buy and raises the price target from $21 to $22.

FOLD

UBS Maintains Buy on Amicus Therapeutics, Raises Price Target to $22

UBS analyst Peter Grom maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Neutral and raises the price target from $60 to $62.

UBS Maintains Neutral on Estee Lauder Cos, Raises Price Target to $62

UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $160 to $170.

UBS Maintains Buy on Cardinal Health, Raises Price Target to $170

UBS analyst Kevin Caliendo maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Neutral and raises the price target from $67 to $71.

UBS Maintains Neutral on CVS Health, Raises Price Target to $71

UBS analyst Eliana Merle maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Buy and lowers the price target from $78 to $70.

MRNA

UBS Maintains Buy on Moderna, Lowers Price Target to $70

Casey's General Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) has outperformed the market over the past 5 years by 9.81% on an annualized basis producing an average annual return of 24.45%. Currently, Casey's General Stores has a market capitalization of $16.70 billion. 
Buying $100 In CASY: If an investor had bought $100 of CASY stock 5 years ago, it would be worth $299.50 today based on a price of $458.65 for CASY at the time of writing.
<h3>Casey's General Stores's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746225012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CASY

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Press Releases

Verrica Provides Business and Operational Update

Health Care

Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference

Comments

Verrica Pharmaceuticals

Vendite allo scoperto

Verrica Pharmaceuticals (NASDAQ:VRCA) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO